Bill 119 hr 679 aims to reverse changes made by the Food and Drug Administration (FDA) in January 2023 regarding the risk evaluation and mitigation strategy for the abortion pill mifepristone. The bill seeks to nullify these modifications and return to the previous regulations in place.
The FDA's modifications to the risk evaluation and mitigation strategy for mifepristone have been a point of contention, with some arguing that the changes have made it more difficult for individuals to access the medication. This bill is intended to address these concerns and ensure that individuals have continued access to mifepristone for medical purposes.
In addition to nullifying the FDA's modifications, the bill also includes provisions for other purposes related to the regulation of mifepristone. The specifics of these additional provisions are not detailed in the summary, but they are likely to address various aspects of the regulation and use of the medication.
Overall, Bill 119 hr 679 is focused on reversing recent changes to the risk evaluation and mitigation strategy for mifepristone and ensuring continued access to the medication for medical purposes. The bill is likely to spark debate and discussion among lawmakers and stakeholders in the healthcare and reproductive rights communities.